KURA: SEC Form 8-K filed by Kura Oncology Inc.
Stocks in this Quantisnow insightHealth Care
Historical context for KURA
Across the 30 sessions after earlier KURA headlines, the stock closed higher 17 times and lower 13 times, with a median move of 2.2% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | KURA | SPY |
|---|---|---|---|
| Sep 9, 2026 | Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes | -3.4% | -0.5% |
| Sep 8, 2026 | Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer | -5.5% | -0.5% |
| Sep 4, 2026 | Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | +0.8% | -0.4% |
| Sep 1, 2026 | Kura Oncology to Participate in Three Investor Conferences in September | +1.9% | -0.7% |
| Aug 13, 2026 | Kura Oncology Reports Second Quarter 2026 Financial Results | +1.5% | +0.7% |
| Aug 10, 2026 | Kura Oncology Announces Publication in Blood Highlighting Ziftomenib’s Differentiated Binding Profile and Preclinical Activity | +2.9% | -0.0% |
Quantisnow market dataNASDAQ
KURA
Kura Oncology Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for KURA
Full KURA profile on Quantisnow Follow KURA and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time